Comparative Pharmacology
Head-to-head clinical analysis: CAVERJECT IMPULSE versus DINOPROSTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAVERJECT IMPULSE versus DINOPROSTONE.
CAVERJECT IMPULSE vs Dinoprostone
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alprostadil is a synthetic prostaglandin E1 that causes vasodilation and relaxation of trabecular smooth muscle in the corpus cavernosum, leading to increased blood flow and penile erection.
Prostaglandin E2 (PGE2) agonist; stimulates uterine smooth muscle contractions, promotes cervical ripening by increasing collagenase activity and softening connective tissue, and induces gap junction formation between myometrial cells.
2.5 to 60 mcg intracavernosal injection as needed for erection, maximum 3 times per week with at least 24 hours between doses. Initial dose: 2.5 mcg, titrate based on response.
Cervical ripening: 0.5 mg dinoprostone gel (Prepidil) intracervically every 6 hours as needed, max 3 doses in 24 hours; or 10 mg vaginal insert (Cervidil) placed transversely in posterior vaginal fornix, removed after 12 hours or at onset of active labor. Termination of pregnancy: 20 mg vaginal suppository (Prostin E2) every 3-5 hours until abortion, max 240 mg total.
None Documented
None Documented
Clinical Note
moderateDinoprostone + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Dinoprostone."
Clinical Note
moderateDinoprostone + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Dinoprostone."
Clinical Note
moderateDinoprostone + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Dinoprostone."
Clinical Note
moderateTiaprofenic acid + Dinoprostone
Terminal elimination half-life is approximately 1-2.5 minutes following intravenous administration, due to rapid pulmonary metabolism; after intracavernosal injection, local half-life is extended to about 30-60 minutes due to depot effect.
Terminal elimination half-life is 2.5-5 minutes due to rapid metabolism in the lungs; clinical effects persist longer due to tissue binding.
Primarily metabolized in the lung by enzymatic hydrolysis; urinary excretion accounts for approximately 70-90% of the administered dose as metabolites, with less than 3% excreted unchanged in urine; fecal excretion is minimal (<1%).
Approximately 90% metabolized in the lung, liver, and kidney; metabolites excreted in urine (primary) and feces. Less than 1% excreted unchanged in urine.
Category C
Category A/B
Prostaglandin
Prostaglandin
"The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Tiaprofenic acid."